CTHRC1: A Biomarker for Evaluation of Rheumatoid Arthritis Disease Activity

NCT ID: NCT04415502

Last Updated: 2020-06-04

Basic Information

• Recruitment Status: UNKNOWN
• Total Enrollment: 100 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2020-10-01
• Study Completion Date: 2021-05-01

Brief Summary

The purpose of the study is to determine whether plasma levels of the collagen triple helix repeat containing (CTHRC1) protein can serve as a blood-based biomarker for diagnosis of rheumatoid arthritis (RA) ,and furthermore its correlation with disease activity

Detailed Description

Rheumatoid arthritis (RA) is a chronic, progressive, autoimmune disease of synovial joints. Characterized by periods of flares with high disease activity involving both a systemic immune response and tissue-specific inflammatory events that can lead to erosive joint and bone destruction and subsequent disability . Currently, diagnosis of RA is based mainly on the extent of tenderness and swelling of the joints , levels of acute-phase reactants such as C-reactive protein (CRP) ,erythrocyte sedimentation rate(ESR) , high titers of rheumatoid factor (RF) and high titers of antibodies against cyclic citrullinated peptide (anti-CCP) in the plasma .Recently, reported increased levels of collagen triple helix repeat containing 1 protein (CTHRC1) are strongly associated with the severity of murine proteoglycan-induced arthritis and collagen antibody-induced murine arthritis (CAIA) , further CTHRC1 expression in murine experimental arthritis is increased in the synovium and specifically detected in activated murine , located at the synovial intimal lining and at the bone-pannus interface .Of interest,The expression pattern of CTHRC1 in pannus, its role in the function of FLS relevant to cartilage damage in RA, and CTHRC1's association with disease severity in murine arthritis raised the question of whether CTHRC1 could be used as a marker for RA diagnosis and monitoring of disease activity in patients .

Conditions

Rheumatoid Arthritis

Study Design

• Observational Model Type: CASE_CONTROL
• Study Time Perspective: PROSPECTIVE

Study Groups

Measuring of CTHRc1 , its correlation with RAdisease activity

Measuring of CTHRc1 levels and its correlation with RA disease activity

No interventions assigned to this group

Eligibility Criteria

Inclusion Criteria

• patients diagnosed as RA
• age more than 18 years

Exclusion Criteria

• other rheumatological diseases Malignancies Hepatic diseases

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Assiut University

OTHER

Sponsor Role: lead

Responsible Party

Lobna Amer Araby Ahmed

Principal investigator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Central Contacts

Lobna Amer Araby Ahmed, Master

Role: CONTACT

Lobnaamer20@gmail.com

01019313530

References

Chewick S. Infection control demand administrative support. Dimens Health Serv. 1975 Dec;52(12):40-1. No abstract available.

Reference Type: BACKGROUND

PMID: 1305 (View on PubMed)

Lumholtz IB. [Nurses' drug information: therapeutic action group: benzodiazepine derivatives. 2]. Sygeplejersken. 1975 Sep 24;75(38):15. No abstract available. Danish.

Reference Type: BACKGROUND

PMID: 803 (View on PubMed)

Other Identifiers

CTHRC1 in RA

Identifier Type: -

Identifier Source: org_study_id